PeptivaLabs products are strictly intended for scientific research purposes. Access to this site requires confirmation of researcher status.
By entering this site, I confirm that:
I am 21 years of age or older I am a licensed researcher, scientist, or qualified professional I understand all products are for in-vitro / laboratory research use only I will not use any products for human or veterinary consumption
FOR RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION · NOT FOR VETERINARY USE
These statements have not been evaluated by the FDA.
Browse 118 of the most researched peptides — COA-verified and blockchain-authenticated. Filter by category, research area, or keyword.
Four mechanism pillars — angiogenesis, growth-factor modulation, NO signaling, and gastric mucosal protection — with citations from the Sikirić, Hsieh, and Krivic literature.
The copper-binding chemistry that makes GHK-Cu unique, plus collagen-synthesis, wound-healing, and gene-expression research from Pickart, Maquart, and Pollard.
Receptor profiles side-by-side, Phase 3 readouts from SURPASS / SURMOUNT / TRIUMPH, and what the glucagon receptor adds mechanistically.
What "99%+ purity" actually means at 214 nm, how mass spectrometry confirms identity, and how to read a real Certificate of Analysis like a chemist.
The counterfeit problem in the research peptide market, how NFC chips and Authentichain blockchain records solve it, and the 10-second verification flow.
The cofactor at the heart of mitochondrial function, sirtuin biology, DNA repair, and the science of cellular aging — with citations from Imai, Verdin, Yoshino, and the NADPARK trial.
The GHRH analog with the largest clinical-research footprint in visceral adipose tissue and IGF-1 modulation studies.
Thymosin β-4 fragment, actin regulation, angiogenesis, and the systemic-repair literature that paired it with BPC-157 in research models.
Melanocortin receptor signaling, the Palatin and AMAG clinical programs, and the central-nervous-system research distinguishing PT-141 from peripheral mechanisms.
Cardiolipin binding, mitochondrial membrane stabilisation, and the cardiac + neurodegenerative research that drove SS-31 into Phase 3.
From exenatide to retatrutide: a research history of incretin therapeutics and where the next decade of metabolic compounds is heading.